THU0610 Serum calprotectin levels in behÇet’s disease: relationships between disease activity and clinical parameters

Abstract

BackgroundBehçet’s disease (BD) is an inflammatory disease with chronic systemicvasculitis. The disease is characterised by attacks of oral and genital ulcers, skin lesions, arthritis, uveitis and deep vein thrombosis. The main histopathologic feature is known to be vascular inflammatory changes. Calprotectin is expressed by granulocytes, monocytes and endothelial cells, and produce an inflammatory response in human microvascular endothelial cells.ObjectivesThe aim of this study was to evaluate serum calprotectin levels and their relationships with disease-related variables in patients with BD.MethodsForty-eight patients diagnosed with BD according to International Study Group of BD classification criteria and 22 demographically matched healthy control subjects participated in this study. Calprotectin levels were measured in blood samples from patients and controls. The disease durations of the patients were between 1 and 28 years. The Behçet’s Disease Current Activity Form (BDCAF), that scores the history of clinical features presenting during four weeks prior to the day of assessment, and Behçet’s Syndrome Activity Scale (BSAS) were used for the evaluation of disease activity.ResultsMean serum calprotectin levels were significantly higher in patients withBD compared to the control group (60.6±43.8, 37.6±37.5, respectively; p=0.037) (Figüre 1). Distribution of age (years; 40.6±12.9, 46.6±11.4, respectively; p=0.075) and sex (male; 62.5%, 45.5%, respectively, p=0.191) between these groups were similar. In the comparison of the calprotectin levels of the patients with or without the components of BD, we found significantly higher levels of calprotectin in patients with oral and genital ulceration versus without these involvements (table 1). Since there were only 2 uveitis patients in this patient group, no calculations were made on uveitis. Serum calprotectin was significantly associated with BDCAF, BSAS, patient’s impression of disease activity, clinician’s impression of disease activity, ESR (Erythrocyte sedimentation rate) and CRP (C-reactive protein) (table 2).Abstract THU0610 – Table 1Comparison of calprotectin levels of patients with or without the components of disease activity(n)Calprotectin (ng/ml)P value Oral ulcerationyes29 no1973.2±46.241.4±32.30.007Genital ulcerationyes9 no3994.5±45.652.8±40.00.009Erythema nodosumyes5 no4382.9±45.158.0±43.50.23Skin pustulesyes18 no3066.0±48.757.3±41.10.51Arthritisyes15 no3357.5±43.162.1±44.70.74Vascular activationyes9 no3959.5±52.360.9±42.40.93Abstract THU0610 – Table 2Correlation between calprotectin level and disease characteristics in patients with BDCalprotectinp BSAS0.4090.004BDCAF0.3750.009Patient’s impression of disease activity0.4010.005Clinician’s impression of disease activity0.3850.007ESR0.4400.002CRP0.3120.031Abstract THU0610 – Figure 1Serum calprotectin levels in BD and control groupsConclusionsOur study demonstrated that serum calprotectin levels were significantly higher in patients with BD relative to the control group, and were significantly correlated...